Trinity College Dublin

Skip to main content.

Top Level TCD Links

Lorraine O'Driscoll
Professor, Pharmacy

Biography

Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD) Lorraine holds a BSc(Hons),pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU. Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer. She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from 27 European countries, 3 US universities, Australia and 7 industry partners. She has developed tailored courses for academia (e.g. FEBS), semi-state bodies (e.g. IDA) and industry. Her graduates are now employed at NIH; Pfizer; Amgen; Leo; Roche; AstraZeneca; ICON plc; entrepreneur/company CEO; Manager of Research Centre; others in academia.

Publications and Further Research Outputs

Peer-Reviewed Publications

O'Driscoll L, Stoorvogel W, Thery C, Buzas E, Nazarenko I, Siljander P, Yanez-Mo M, Fais S, Giebel B, Yliperttula M, European Network on Microvesicles and Exosomes in Health and Disease, Eurupean Journal of Pharmaceutical Sciences, 98, 2017, p1 - 3 Journal Article, 2017 DOI URL

MicroRNA Profiling of Exosomes in, editor(s)Rani S (ed.) , Methods in Molecular Biology, New York, Springer, 2017, pp37 - 46, [Daly M, O'Driscoll L] Book Chapter, 2017 URL TARA - Full Text

Vanesa G. Martinez, John Crown, Richard K. Porter, Lorraine O'Driscoll, Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer, International Journal of Cancer, 2017, p2771 - 2784 Journal Article, 2017 DOI URL

Breslin S, Lowry M, O'Driscoll L, Neratinib-resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4, British Journal of Cancer, 2017, p620-625 Journal Article, 2017 URL DOI

Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome in, editor(s)Rani S (ed.) , Meth. Mol.. Biol., New York, Springer, 2017, pp141 - 149, [O'Neill S, O'Driscoll L] Book Chapter, 2017 URL TARA - Full Text

EV-TRACK Consortium, Van Deun J, Mestdagh P, Agostinis P, Akay Ö, Anand S, Anckaert J, Martinez ZA, Baetens T, Beghein E, Bertier L, Berx G, Boere J, Boukouris S, Bremer M, Buschmann D, Byrd JB, Casert C, Cheng L, Cmoch A, Daveloose D, De Smedt E, Demirsoy S, Depoorter V, Dhondt B, Driedonks TA, Dudek A, Elsharawy A, Floris I, Foers AD, Gärtner K, Garg AD, Geeurickx E, Gettemans J, Ghazavi F, Giebel B, Kormelink TG, Hancock G, Helsmoortel H, Hill AF, Hyenne V, Kalra H, Kim D, Kowal J, Kraemer S, Leidinger P, Leonelli C, Liang Y, Lippens L, Liu S, Lo Cicero A, Martin S, Mathivanan S, Mathiyalagan P, Matusek T, Milani G, Monguió-Tortajada M, Mus LM, Muth DC, Németh A, Nolte-'t Hoen EN, O'Driscoll L, Palmulli R, Pfaffl MW, Primdal-Bengtson B, Romano E, Rousseau Q, Sahoo S, Sampaio N, Samuel M, Scicluna B, Soen B, Steels A, Swinnen JV, Takatalo M, Thaminy S, Théry C, Tulkens J, Van Audenhove I, van der Grein S, Van Goethem A, van Herwijnen MJ, Van Niel G, Van Roy N, Van Vliet AR, Vandamme N, Vanhauwaert S, Vergauwen G, Verweij F, Wallaert A, Wauben M, Witwer KW, Zonneveld MI, De Wever O, Vandesompele J, Hendrix A., EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research., Nature Methods, 14, (3), 2017, p228 - 232 Journal Article, 2017 URL DOI

O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L., Blood-based biomarkers for metabolic syndrome, Trends in Endocrinology & Metabolism, 2016, p363 - 374 Journal Article, 2016 TARA - Full Text URL DOI

Breslin S, O'Driscoll L, The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance., Oncotarget, 7, (29), 2016, p45745 - 45756 Journal Article, 2016 TARA - Full Text DOI

Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, A, Sammar M, Llorente A, Nazarenko I, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Bedina Zavec A, Giebel B., Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine, ASC Nano, 10, (4), 2016, p3886 - 3899 Journal Article, 2016 URL DOI

O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L., miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity., Oncotarget, 6, (32), 2015, p32 - 41 Journal Article, 2015 URL DOI TARA - Full Text

Analysis of changes in phosphorylation of Receptor Tyrosine Kinases: antibody arrays in, Meth. Mol. Biol., 2015, pp15 - 23, [Rani S, O'Driscoll L] Book Chapter, 2015 TARA - Full Text DOI URL

Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors. in, Meth. Mol. Biol., 2015, pp169 - 180, [Corcoran C, O'Driscoll L] Book Chapter, 2015 DOI URL

Receptor tyrosine kinase targeting in multicellular spheroids. in, Meth. Mol. Biol., 2015, pp161 - 168, [Breslin S, O'Driscoll L] Book Chapter, 2015 URL TARA - Full Text DOI

Martinez VG, Rani S, Corcoran C, Crown J, O'Driscoll L., Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells., J Clin. Oncol., American Society for Clinical Oncology, Chicago, 29/5-6/2/2015, 33, (15), ASCO University, 2015, pp614- Published Abstract, 2015 TARA - Full Text URL

Lowry MC, Gallagher WM, O'Driscoll L., The role of exosomes in breast cancer, Clinical Chemistry, 61, (12), 2015, p1457 - 1465 Journal Article, 2015 URL TARA - Full Text

Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O'Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B. , Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper., Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. , 30087, (4), 2015, p1 - 35 Journal Article, 2015 DOI URL TARA - Full Text

Martinez VG, O'Driscoll L, Neuromedin U: A Multifunctional Neuropeptide with Pleiotropic Roles., Clin. Chem., 61, (3), 2015, p471-82 Journal Article, 2015 DOI URL TARA - Full Text

Bohl M, Bjørnshave A, Rasmussen KV, Grethe Schioldan A, Amer B, Larsen MK, Dalsgaard TK, Holst JJ, Herrmann A, O'Neill S, O'Driscoll L, Afman L, Jensen E, Christensen MM, Gregersen S, Hermansen K. , Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. , Amer. J. Clin. Nutrition. , 101, (4), 2015, p870 - 878 Journal Article, 2015 URL DOI TARA - Full Text

O'Driscoll L., Expanding on Exosomes and Ectosomes in Cancer, New Eng. J. Medicine, 372, (24), 2015, p2359 - 2362 Journal Article, 2015 DOI URL TARA - Full Text

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O, Biological properties of extracellular vesicles and their physiological functions., J. Extracellular Vesicles, 4, 2015, p27066 Journal Article, 2015 TARA - Full Text URL DOI

Lowry MC, Gallagher WM, O'Driscoll L, The Role of Exosomes in Breast Cancer, Clin. Chem., 16, (clinchem.2015.240028), 2015, p1457 - 1465 Journal Article, 2015 DOI TARA - Full Text URL

O'Neill S, O'Driscoll L, Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. , Obes. Rev., 16, (1), 2015, p1-12 Journal Article, 2015 URL DOI TARA - Full Text

Kumar Jella K, Rani S, O'Driscoll L, McClean B, Byrne HJ, Lyng FM. , Exosomes are involved in mediating radiation induced bystander signaling in human keratinocyte cells. , Radiat. Res. , 181, (2), 2014, p138 - 145 Journal Article, 2014 TARA - Full Text URL DOI

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L, Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors., Cancer Research, 74, (14), 2014, p3821 - 3833 Journal Article, 2014 URL DOI TARA - Full Text

Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L, miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer , Mol. Cancer, 13, 2014, p71 - 79 Journal Article, 2014 TARA - Full Text URL DOI

Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N, Predictive biomarkers for dasatinib treatment in melanoma , Oncoscience, 1, (2), 2014, p158 - 166 Journal Article, 2014 TARA - Full Text URL DOI

O'Brien K, Corcoran C, Rani S, Crown J, Radomski M, O'Driscoll L., miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression., J. Extracell. Vesicles., International Society for Extracellular Vesicles, Rotterdam, The Netherlands, 05/2014, 3, (24214), Co-Action Publishing, 2014, pp143 - 144 Published Abstract, 2014 URL TARA - Full Text DOI

Corcoran C, Rani S, Prencipe M, O'Neill A, Watson W, O'Driscoll L. , miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. , J. Extracell. Vesicles. , International Society for Extracellular Vesicles, Rotterdam, The Netherlands, 05/2014, 3, (24214), Co-Action Publishing, 2014, pp360 - 360 Published Abstract, 2014 DOI TARA - Full Text URL

Corcoran C, Rani S, O'Driscoll L, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression., The Prostate, 74, (13), 2014, p1320 - 1334 Journal Article, 2014 DOI URL TARA - Full Text

O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L, Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. , Eur. J. Cancer, 49, (8), 2013, p1845 - 1859 Journal Article, 2013 DOI TARA - Full Text URL

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M. , Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis., Carcinogenesis, 34, (10), 2013, p2300 - 2308 Journal Article, 2013 TARA - Full Text DOI URL

Breslin S, Corcoran C, Rani S, Crown J, O'Driscoll L. , Assessment of neratinib-resistance and cross-resistance in HER2-overexpressing breast cancer cells. , J. Clin. Oncol. , Amer. Soc. Clin. Oncol., Chicago, US, 06/2013, 31, (15S), 2013, pp11520 - 11521 Published Abstract, 2013 URL TARA - Full Text

Breslin S, O'Driscoll L, 3-Dimensional cell culture: the missing link in drug discovery., Drug Discovery Today, 18, (5-6), 2013, p240 - 249 Review Article, 2013 URL TARA - Full Text DOI

O'Brien K, Corcoran C, Rani S, McDonnell S, Hughes L, Radomski M, Crown J, O'Driscoll L. , The Relevance of exosomal-miRNAs in triple-negative breast cancer progression. , J. Extracell. Vesicles., International Society for Extracellular Vesicles, Boston, US, 04/2013, 2, Co-Action, 2013, pp122 - 122 Published Abstract, 2013 URL DOI TARA - Full Text

Breslin, S., O'Driscoll, L., Three-dimensional cell culture: The missing link in drug discovery, Drug Discovery Today, 18, (5-6), 2013, p240 - 249 Journal Article, 2013 DOI TARA - Full Text URL

Corcoran C, Rani S, Breslin S, Ghobrial IM, Crown J, O'Driscoll L., The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol., Amer. Soc. Clin. Oncol., Chicago, US, 06/2013, 31, (15S), 2013 Published Abstract, 2013 URL TARA - Full Text

Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L, Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma., Cancer biology & therapy, 14, (12), 2013, p1104-12 Journal Article, 2013 TARA - Full Text URL DOI

Hill AF, Pegtel DM, Lambertz U, Leonardi T, O'Driscoll L, Pluchino S, Ter-Ovanesyan D, Nolte-'t Hoen EN. , ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. , J. Extracell. Vesicles., 2013, p22859- Review Article, 2013 TARA - Full Text DOI URL

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ , Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. , Cancer Biol Ther. , 14, (6), 2013, p537 - 545 Journal Article, 2013 DOI URL TARA - Full Text

Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , EGFR and HER2 inhibition in pancreatic cancer. , Invest. New Drugs, 31, (3), 2013, p558 - 566 Journal Article, 2013 DOI URL TARA - Full Text

Eustace AJ, Browne B, Madden SF, O'Driscoll L, McDermott M, O'Brien NA, Watson W, Crown J, Walsh N, O'Donovan N. , Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX. , J. Clin. Oncol. , Amer. Soc. Clin. Oncol., Chicago, US, June 2012, 30, (15), 2012 Published Abstract, 2012 TARA - Full Text URL

Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L. , Generation and Characterisation of Neratinib-resistant Breast Cancer Cell Line Variants., Eur. J. Cancer, Europ. Soc. Med. Oncol., 09/2012, 48, 2012, pp32 - 33 Published Abstract, 2012 URL TARA - Full Text DOI

Rani S, Germano S, Madden SF, Corcoran C, Breslin S, O'Brien NA, McDermott M, Browne B, O'Donovan N, Crown J, O'Driscoll L. , Neuromedin U: A potential predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol. , Amer. Soc. Clin. Oncol., Chicago, US, 06/2012, 30, (15), 2012 Published Abstract, 2012 TARA - Full Text URL

Corcoran C, Rani S, O'Neill A, Prencipe M, O'Brien A, O'Brien K, Crown J, Watson WG, O'Driscoll L. , The relevance of exosomes in prostate cancer and their potential to confer docetaxel resistance to secondary cells. , Cancer Research , 72, (8), 2012, pp794 - 795 Published Abstract, 2012 DOI URL TARA - Full Text

Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I, Radomski A, Jow H, Sawicki G, Radomski MW., Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. , Brit. J. Pharmacol., 167, (4), 2012, p787 - 804 Journal Article, 2012 DOI TARA - Full Text URL

Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L., MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis., Int J Cancer, 130, 2012, p1991 - 2002 Journal Article, 2012 URL TARA - Full Text DOI

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, Mc Dermott R, Watson W, Crown J, O'Driscoll L. , Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. , PloS One, 7, (12), 2012, p50999- Journal Article, 2012 DOI TARA - Full Text URL

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Crown J, Watson W, O'Driscoll L. , Exosomes: potential regulators and biomarkers of prostate cancer progression. , J. Extracell. Vesicles., International Society for Extracellular Vesicles, Gothenburg, Sweden, April 2012, 51, (76), 2012, pp34 - 35 Published Abstract, 2012 TARA - Full Text DOI URL

O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Meleady P, O'Driscoll L, Watson W, O'Connor R. , The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. , Proteomics, 12, (13), 2012, p2115 - 2126 Journal Article, 2012 URL TARA - Full Text DOI

Chen X, Hermansen K, Xiao J, Bystrup SK, O`Driscoll L, Jeppesen PB. , Isosteviol has beneficial effects on palmitate-induced α-cell dysfunction and gene expression. , PLoS One , 7, (3), 2012, p34361 - 34369 Journal Article, 2012 URL DOI TARA - Full Text

O'Brien K, Rani S, Wallace R, McDonnell S, Hughes L, Radomski M and O'Driscoll L. , Can exosomes influence triple negative breast cancer metastasis?, J. Extracell. Vesicles., International Society for Extracellular Vesicles, Gothenburg, Sweden, April 2012, 51, 2012, pp74 - 75 Published Abstract, 2012 URL TARA - Full Text DOI

Eustace AJ, Browne BC, McDermott M, O'Leary P, O'Driscoll L, O'Brien N, Gallagher N, Watson W, Crown J, O'Donovan N. , Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive, Eur. J. Cancer, Europ. Soc. Med. Oncol., 09/2012, 48, 2012, pp44 - 45 Published Abstract, 2012 TARA - Full Text DOI URL

Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L., Intracellular and extracellular microRNAs in breast cancer., Clin Chem. , 57, (1), 2011, p18 - 32 Journal Article, 2011 TARA - Full Text DOI URL

Rani S, O'Brien K, Kelleher FC, Corcoran C, Germano S, Radomski MW, Crown J, O'Driscoll L., Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling., Methods Mol Biol., 784, 2011, p181 - 195 Journal Article, 2011 URL DOI TARA - Full Text

O'Driscoll L, O'Byrne K, LUNGMARK, 2011, US20130059742 Patent, 2011 URL

O'Driscoll L, Rani S, Marker and Target for Responsiveness and Resistance to Cancer Agents, 2011, WO2013057323 Patent, 2011 URL

Eustace AJ, Kennedy S, Larkin A, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. , J. Clin. Oncol., Amer. Soc. Clin. Oncol., Chicago, US, 2011, 29, (15), 2011 Published Abstract, 2011 TARA - Full Text URL

Corcoran C, Rani S, O'Brien K, Crown J, O'Driscoll L. , Establishing and characterising new in vitro models of docetaxel-resistance in prostate cancer. , Eur. J. Cancer, Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp489 - 490 Published Abstract, 2011 DOI URL

O'Driscoll L. , microRNAs-key contributors to endocrinology. , BioScientifica, 25, (4), 2011, pp1- Published Abstract, 2011 TARA - Full Text URL

Germano S, O'Driscoll L., Western blotting analysis as a tool to study receptor tyrosine kinases., Methods Mol Biol. , 784, 2011, p109 - 121 Journal Article, 2011 DOI URL TARA - Full Text

Rani S, O'Driscoll L. , Function of beta cell and extracellular RNAs as potential biomarker. Defining beta cell function and elucidating extracellular RNAs as potential biomarker. , Academic Press, 2011 Book, 2011

O'Neill, AJ, Prencipe, M, Dowling, C, Fan, Y, Mulrane, L, Gallagher, WM, O'Connor, D, O'Connor, R, Devery, A, Corcoran, C, Rani, S, O'Driscoll, L, Fitzpatrick, JM, Watson, RWG, Characterisation and manipulation of docetaxel resistant prostate cancer cell lines, MOLECULAR CANCER, 10, (126), 2011 Journal Article, 2011 DOI URL TARA - Full Text

Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. , Investigating clinical and functional relevance of MAGE-D4B in breast cancer. , Ir. J. Med. Sci. , 180, 2011, pp295- Published Abstract, 2011

Rani S, O'Driscoll L., Reverse-transcriptase polymerase chain reaction to detect extracellular mRNAs., Methods Mol Biol. , 784, 2011, p15 - 25 Journal Article, 2011 TARA - Full Text URL DOI

Hennessy E, O'Driscoll L., MicroRNA expression analysis: techniques suitable for studies of intercellular and extracellular microRNAs., Methods Mol Biol., 784, 2011, p99 - 107 Journal Article, 2011 DOI URL TARA - Full Text

O'Driscoll, L., Editorial: Preface: Gene expression profiling methods and protocols second edition, Methods in Molecular Biology, 784, 2011 Journal Article, 2011

Rani S, O'Brien K, McDonnell S, Hughes L, AFriel AM, Radomski MW, Crown J, O'Driscoll L. , Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes. , Eur. J Cancer , Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp143 - 144 Published Abstract, 2011 TARA - Full Text URL DOI

Friel, A.M., Crown, J., O'Driscoll, L., Analysis of gene expression as relevant to cancer cells and circulating tumour cells, Methods in Molecular Biology, 784, 2011, p55-75 Journal Article, 2011

Corcoran S, Rani S, O'Brien K, O'Neill A, Watson W, Crown J, O'Driscoll L. , The use of in vitro cell line models to investigate docetaxel-resistance in prostate cancer., Ir. J. Med. Sci. , 2011, 180, 2011, pp287 - 288 Published Abstract, 2011

Sheridan H, Nestor C, O'Driscoll L, Hook I., Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii., J Nat Prod., 71, (1), 2011, p82 - 85 Journal Article, 2011 DOI URL TARA - Full Text

Lewis A Chodosh(ed.), Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer, Breast Cancer Research, London, 12, (1), 18 May 2010, BioMed Central, 2010, 32 p Proceedings of a Conference, 2010 URL TARA - Full Text

Hennessy E, Clynes M, Jeppesen P, O'Driscoll L, Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells., Biochemical and Biophysical Research Communications, 396, (2), 2010, p457 - 462 Journal Article, 2010 TARA - Full Text URL DOI

Friel AM, Corcoran C, Crown J, O'Driscoll L., Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer., Breast Cancer Res Treat. , 123, (3), 2010, p613 - 615 Journal Article, 2010 TARA - Full Text URL DOI

Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L, Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis, British Journal of Cancer, 102, 2010, p1157-1162 Journal Article, 2010 DOI URL TARA - Full Text

Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, Clynes M, O'Driscoll L, Decreasing Txnip mRNA and Protein Levels in Pancreatic MIN6 Cells Reduces Reactive Oxygen Species and Restores Glucose Regulated Insulin Secretion., Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 25, (6), 2010, p667-674 Journal Article, 2010 DOI

P Doolan, M Clynes, S Kennedy, JP Mehta, S Germano, C Ehrhardt, J Crown, L O'Driscoll, TMEM25, REPS2 and Meis 1: Favourable prognostic and predictive biomarkers for breast cancer, Tumor Biol, 30, (4), 2009, p200-209 Journal Article, 2009 URL DOI

Gene Expression Profiling, L O'Driscoll, 2nd Edition, New York:, Humana Press, 2009, 1 - 211 Critical Edition (Book), 2009 TARA - Full Text

Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O Driscoll L., Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma, BMC Urology, 24, (9), 2009, p6- Journal Article, 2009 DOI TARA - Full Text URL

Current Cancer Drug Targets, Bentham Science Publishers Ltd., 2009, - Critical Edition (Book), 2009 TARA - Full Text

O'Driscoll, L.,., Doolan, P., Clynes, M, 'Diagnostic, prognostic and/or predictive indicators of breast cancer', Publ.of the Int.Appl. without Int.search REP. - World Intellectual Property Organization, WO 2008132167 A3, 2009, 18 May 2009 Patent, 2009

Germano S, O'Driscoll L, Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to aid in Personalised Medicine, Curr Cancer Drug Targets, 9, (3), 2009, p398 - 418 Journal Article, 2009 DOI TARA - Full Text URL

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R., Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines., Invest New Drugs, 28, (4), 2009, p433 - 444 Journal Article, 2009 DOI TARA - Full Text URL

Germano S, Kennedy S, Hughes L, McDonnell S, Mehta JP, Doolan P, Clynes M, O'Driscoll L, Characterisation of Neuronal Calcium Sensor-1 (NCS-1) as a novel prognostic biomarker with potential therapeutic implications for triple negative breast cancer, Ann Oncol, 20, (2), Oxford Journals; Oxford University Press, 2009, pp49 - 50 Meeting Abstract, 2009

O'Driscoll L, Mechanisms of drug sensitivity and resistance in cancer., 2009 Journal Article, 2009

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L., Prevalence and prognostic and predictive relevance of PRAME in breast cancer, Breast Cancer Res. Treat. , 109, (2), 2008, p359 - 365 Journal Article, 2008 DOI TARA - Full Text URL

Hennessy E, O'Driscoll L., Molecular medicine of microRNAs: structure, function and implications for diabetes., Expert Rev Mol Med. , 10, 2008, pEpub e14-- Journal Article, 2008 URL DOI TARA - Full Text

O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, Hill A, O'Daly B, O'Gorman D, Clynes M., Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR., Cancer Genomics Proteomics, 5, (2), 2008, p94 - 104 Journal Article, 2008 URL TARA - Full Text

Dowling P, Shields W, Rani S, Meleady P, Henry M, Jeppesen P, O'Driscoll L, Clynes M., Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction., Electrophoresis, 29, (20), 2008, p4141 - 4149 Journal Article, 2008 URL TARA - Full Text DOI

Kennedy S, Clynes M, Doolan P, Mehta JP, Rani S, Crown J, O'Driscoll L., SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue., Brit. J. Cancer, 98, (10), 2008, p1641 - 1645 Journal Article, 2008 TARA - Full Text URL DOI

Martinez V, Kennedy S, Doolan P, Gammell P, Joyce H, Kenny E, Prakash Mehta J, Ryan E, O'Connor R, Crown J, Clynes M, O'Driscoll L., Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue., Breast Cancer Res. Treat. , 110, (3), 2008, p521 - 530 Journal Article, 2008 DOI TARA - Full Text URL

Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M., Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines., Eur. J. Cancer, 44, (1), 2008, p151 - 159 Journal Article, 2008 URL DOI TARA - Full Text

O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L., Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents., Expert Opin Drug Metab Toxicol. , 3, (6), 2007, p805 - 817 Journal Article, 2007 DOI URL TARA - Full Text

Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, Crown J, O'Driscoll L., MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer., Anticancer Res., 27, 2007, p1325 - 1330 Journal Article, 2007 TARA - Full Text URL

Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, Moriarty M, Crown J, Clynes M., 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins., Electrophoresis, 28, (23), 2007, p4302 - 4310 Journal Article, 2007 URL DOI

Mc Kiernan E, Barron NW, O'Sullivan F, Barham P, Clynes M, O'Driscoll L., Detecting de novo insulin synthesis in embryonic stem cell-derived populations., Exp. Cell Res. , 313, (7), 2007, p1405 - 1414 Journal Article, 2007 URL TARA - Full Text DOI

O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J., A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer Chemother Pharmacol. , 59, (1), 2007, p79 - 87 Journal Article, 2007 DOI TARA - Full Text URL

Rani S, Clynes M, O'Driscoll L., Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function., Clin. Chem., 53, (11), 2007, p1936 - 1944 Journal Article, 2007 DOI TARA - Full Text URL

O'Driscoll L., Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers., Anticancer Res., 27, (3), 2007, p1257 - 1265 Journal Article, 2007 URL TARA - Full Text

Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P., A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?, Anticancer Res., 27, 2007, p1295 - 1300 Journal Article, 2007 TARA - Full Text URL

O'Driscoll, L., O'Connor, R., Clynes, M., Anticancer Research: Preface, Anticancer Research, 27, (3 A), 2007 Journal Article, 2007

McKiernan E, O'Driscoll L, Kasper M, Barron N, O'Sullivan F, Clynes M., Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes., Tissue Eng., 13, (10), 2007, p2419 - 2430 Journal Article, 2007 URL DOI

O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S., MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma., Anticancer Res., 27, 2007, p2115 - 2120 Journal Article, 2007 TARA - Full Text URL

Keenan J, Pearson D, O'Driscoll L, Gammell P, Clynes M., Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture., Cytotech., 51, (1), 2006, p29 - 37 Journal Article, 2006 DOI URL TARA - Full Text

Breen L, O'Driscoll L, Clynes M. , Gene Expression Microarray Technology: Some Applications in Lung Cancer Research., Cancer Genomics Proteomics, 3, (3-4), 2006, p197 - 202 Journal Article, 2006 TARA - Full Text

O'Driscoll L, Gammell P, McKiernan E, Ryan E, Jeppesen PB, Rani S, Clynes M., Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells., J. Endocrinol. , 191, (3), 2006, p665 - 676 Journal Article, 2006 TARA - Full Text DOI URL

O'Driscoll L, Clynes M., Biomarkers and multiple drug resistance in breast cancer., Curr. Cancer Drug Targets , 6, (5), 2006, p365 - 384 Journal Article, 2006 URL TARA - Full Text DOI

O'Driscoll L, Clynes M., Molecular markers of multiple drug resistance in breast cancer., Chemotherapy, 52(3):125-9, (3), 2006, p125 - 129 Journal Article, 2006 DOI URL TARA - Full Text

Methods in Apoptosis in, Cell Biology: A Laboratory Handbook, International, Elsevier Academic Press, 2006, pp355 - 344, [O'Driscoll L, O'Connor R, Clynes M ] Book Chapter, 2006 URL DOI TARA - Full Text

O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M., Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays., Mol. Cancer, 5, 2006, p74 - 86 Journal Article, 2006 URL DOI TARA - Full Text

Conway CM, O'Shea D, O'Brien S, Lawler DK, Dodrill GD, O'Grady A, Barrett H, Gulmann C, O'Driscoll L et al., The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line., BMC Bioinformatics, 17, (7), 2006, p256 - 268 Journal Article, 2006 URL TARA - Full Text DOI

O'Driscoll L., The emerging world of microRNAs., Anticancer Res., 26 , 2006, p4271 - 4278 Journal Article, 2006 URL TARA - Full Text

Walsh N, Kennedy S, Larkin A, Roy S, Ooi W, Gullo G, Ballot J, Clynes M, Crown J, O'Driscoll L , MDR1/P-Glycoprotein and MRP-1 Protein Expression in Pancreatic (CaP) & Non-Small Cell Lung Cancers (NSCLC). , Ann. Oncol., 17, (9), 2006, p64 - 65 Journal Article, 2006

Dowling P, O'Driscoll L, O'Sullivan F, Dowd A, Henry M, Jeppesen PB, Meleady P, Clynes M., Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress., Proteomics, 6, (24), 2006, p6578 - 6587 Journal Article, 2006 TARA - Full Text URL DOI

Setting up a Cell Culture Laboratory in, editor(s)Julio E. Celis , Cell Biology: A Laboratory Handbook. 3rd Edition , Oxford, UK, Elsevier Academic press, 2006, pp5 - 12, [O'Connor R, O'Driscoll L ] Book Chapter, 2006 URL DOI TARA - Full Text

O'Driscoll L, Kenny E, Perez de Villarreal M, Clynes M, Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. , Cancer Genomics & Proteomics , 2, (1), 2005, p43 - 52 Journal Article, 2005 TARA - Full Text URL

O'Driscoll L, Gammell P, Clynes M., Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development., Transplant Proc. , 36, (4), 2004, p1511 - 1518 Journal Article, 2004 URL TARA - Full Text DOI

Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M., Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study., Int. J. Cancer, 112, (2), 2004, p286 - 294 Journal Article, 2004 DOI URL

Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O'Connor R, Clynes M., Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs., Int. J. Cancer, 111, (4), 2004, p484 - 493 Journal Article, 2004 URL TARA - Full Text DOI

O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M., Expression and prognostic relevance of Mcl-1 in breast cancer., Anticancer Res., 24, (2), 2004, p473 - 482 Journal Article, 2004 URL TARA - Full Text

O'Driscoll, L., O'Connor, R., Clynes, M., "Biotechnology, cancer and drug resistance: New targets, new diagnosis and new treatment for tumours resistant to current therapies". Preface, Anticancer Research, 24, (2 A), 2004 Journal Article, 2004

O'Driscoll L, Gammell P, Clynes M., Mechanisms associated with loss of glucose responsiveness in beta cells., Transplant Proc. , 36, (4), 2004, p1159 - 1162 Journal Article, 2004 DOI TARA - Full Text URL

Gammell P, O'Driscoll L, Clynes M., Characterisation of BHK-21 cells engineered to secrete human insulin, Cytotechnol., 41, (1), 2003, p11 - 21 Journal Article, 2003 DOI URL TARA - Full Text

Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M., Prognostic importance of survivin in breast cancer., Br J. Cancer, 88, (7), 2003, p1077 - 1083 Journal Article, 2003 URL TARA - Full Text DOI

O'Driscoll L, Linehan R, Clynes M., Survivin: role in normal cells and in pathological conditions., Curr. Cancer Drug Targets , 3, (2), 2003, p131 - 152 Journal Article, 2003 URL DOI TARA - Full Text

Clynes M, O'Connor R, O'Driscoll L, Daly C, Meleady P., Challenges in molecular analysis for individualized cancer therapy., Drug Discov. Today, 8, (12), 2003, p531 - 533 Journal Article, 2003 URL TARA - Full Text DOI

O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, W McDermott E, D Hill A, J O'Higgins N, Parkinson M, Clynes M., Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer., Cancer Lett., 201, (2), 2003, p225 - 236 Journal Article, 2003 DOI TARA - Full Text URL

O'Driscoll L, Gammell P, Clynes M., Engineering Vero cells to secrete human insulin, In Vitro Cell Dev. Biol. Anim. , 38, (3), 2002, p146 - 153 Journal Article, 2002 TARA - Full Text URL DOI

O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M., Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro., Anticancer Res., 22, (6), 2002, p3117 - 3125 Journal Article, 2002 URL TARA - Full Text

Coakley, R., O'Neill, S., Coakley, R., Glynn, P., O'Neill, S., Finlay, G.A., Russell, K.J., McMahon, K., D'Arcy, E.M., Masterson, J.B., Fitzgerald, M.X., O'Connor, C.M., O'Driscoll, L.R., Finlay, G.A., Fitzgerald, M.X., O'Connor, C.M., McGarvey, L.P.A., Forsythe, P., Heaney, L.G., MacMahon, J., Ennis, M., Leonard, C., Tormey, V., Burke, C.M., Poulter, L.W., Keatings, V.M., FitzGerald, M.X., Barnes, P.J., Harty, H.R., Corfield, D.R., Adams, L., Schwartzstein, R.M., Kiely, J.F., Buckley, A., Shiels, P., Deegan, P.C., Maurer, B., McNicholas, W.T., Dunlop, K.A., Martin, B., Riley, M., Shields, M.D., Glynn, P., Kilgallen, I., Coakley, R., O'Neill, S., McElvaney, N.G., Cervantes-Laurean, D., Wehr, N., Gabriele, K., Robinson, W., Moss, J., Levine, R.L., Urbach, V., Walsh, D., Harvey, B., McElroy, M.C., Pittet, J.-F., Allen, L., Wiener-Kroonish, J., Dobbs, L.G., O'Donnell, D.M., McMahon, K.J., O'Connor, C., Fitzgerald, M.X., McGuirk, P., Mahon, B., Griffin, F., Mills, K.H.G., Murphy, R., Brijker, F., Mulloy, E., Cohen Tervaert, J.W., Walshe, J., O'Neill, S., McGarvey, L.P.A., Heaney, L.G., Lowry, R.C., Shepherd, D.R.T., MacMahon, J., Gamble, L.A., Carton, C., Memon, R., Winter, D., Chan, A., Aherne, T., O'Reilly, P., Harbison, J.A., McNicholas, W.T., O'Callaghan, S., Mulloy, E., Keane, M., McKenna, M., Woods, S., O'Neill, S., Lamon, A., Leonard, C., Faul, J., Murphy, M., Burke, C.M., Tormey, V., Riley, M., Porszasz, J., Engelen, M.P.K.J., Brundage, B., Wasserman, K., Sweeney, M., O'Regan, R.G., McLoughlin, P., Sweeney, M., Honner, V., Sinnott, B., O'Regan, R.G., McLoughlin, P., Kilgallen, I., O'Neill, S., McGrath, D.S., Kiely, J., Cryan, B., Bredin, C.P., McGrath, D.S., Shortt, C., Stack, M., Kelleher, N., Bredin, C.P., Russell, K.J., McRedmond, J., Mulkerji, N., Keatings, V., Fitzgerald, M.X., O'Connor, C.M., Boylan, G.M., McElroy, M.C., Dobbs, L.G., Forsythe, P., McGarvey, L.P.A., Cross, L.J.M., Ennis, M., Heaney, L.G., MacMahon, J., Davern, S., O'Connor, C.M., McDonnell, T.J., Kiely, J.L., Lawless, G., Cunningham, S., McNicholas, W.T., Lordan, J., Clancy, L., Manning, P., Plunkett, P., Donaghy, D., Kiely, J., McDonnell, T.J., Ben Musbah, F., Loftus, B.G., Ben Musbah, F., Loftus, B.G., Rutherford, R., Watson, S.N.E., Gilmartin, J.J., Henry, M., Mullins, G., Brennan, N., Kiely, J.L., Deegan, P.C., McNicholas, W.T., Irish thoracic society - Proceeds of annual scientific meeting held Friday & Saturday 8th & 9th November, 1996, Irish Journal of Medical Science, 167, (9 Supplement), 1998, p1-13 Journal Article, 1998

Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M., Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance., Int. J. Cancer, 71, (5), 1997, p907 - 915 Journal Article, 1997 URL DOI TARA - Full Text

Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM., Matrix metalloproteinase expression and production by alveolar macrophages in emphysema., Am. J. Respir. Crit. Care Med., 156, (1), 1997, p240 - 247 Journal Article, 1997 DOI URL TARA - Full Text

O'Driscoll L, Kennedy S, McDermott E, Kelehan P, Clynes M., Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue., Eur. J. Cancer, 32, (1), 1996, p128 - 133 Journal Article, 1996 URL TARA - Full Text

O'Driscoll, L.R., Finlay, G.A., Fitzgerald, M.X., O'Connor, C.M., Matrixmetalloproteinases expression by alveolar macrophages in emphysema, Thorax, 51, (SUPPL. 3), 1996 Journal Article, 1996

Daly C, Coyle S, McBride S, O'Driscoll L, Daly N, Scanlon K, Clynes M., mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines., Cytotechnol., 19, (3), 1996, p199 - 205 Journal Article, 1996 TARA - Full Text URL

Clynes M, Heenan M, McBride S, Cleary I, O'Driscoll L, Moran E. , Multiple drug resistance in variants of a human lung cell line exposed to adriamycin and VP-16. , J. Exp. & Clin. Cancer Res. , 14, 1995, p15-16- Journal Article, 1995 TARA - Full Text

O'Driscoll L, Daly C, Saleh M, Clynes M., The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells., Cytotechnol., 12, (1-3), 1993, p289 - 314 Journal Article, 1993 URL TARA - Full Text

Non-Peer-Reviewed Publications

Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2016, S21 p Proceedings of a Conference, 2016

Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2013, S32-33 p Proceedings of a Conference, 2013

Research Expertise

Description

Bi-directional translational research; cancer research; diagnostic biomarkers; prognostic biomarkers; predictive markers; novel therapeutic targets; targeted therapies; pipeline drugs; monoclonal antibodies; small molecules; clinical and industry collaborations; breast cancer; lung cancer; prostate cancer; melanoma; multiple myeloma; circulating tumour cells (CTCs); multi-drug resistance; stem cells; differentiation; diabetes; islet transplants; microarrays; proteomics; mRNAs; microRNAs (miRNAs); clinical trials

Projects

  • Title
    • Exosomal Neuromedin U and miR-X: potential predictive biomarkers for HER2-targeted drugs
  • Summary
    • A new range of anti-cancer drugs have become available that are used to treatment some breast cancer patients. The best known one is Herceptin (trastuzumab), but there are other new drugs in this family. These drugs were designed to interact with HER2, a molecule found at greater amounts on cancer cells compared to normal cells for ~25% of breast cancer patients. These drugs are more cancer-specific than older chemotherapy and can offer advantages of greatly helping many patients without causing serious side-effects. Unfortunately, some patients who seem suitable candidates based on the HER2 test, don't benefit from these treatments. Some others respond at first, but then become unresponsive (resistant) to the treatment. Added to the problem of some patients not benefiting, these drugs are extraordinarily expensive costs to healthcare. We urgently need ways of predicting which patients with "HER2 tumours" are likely to benefit. We also need to be able to overcome the resistance problem. Studying cells from breast tumours, we recently found two molecules, NmU and miR-X, at substantially different amounts both inside and outside cells that are resistant to these drugs compared to those that are sensitive. By "tweaking" their amounts in the cells, we can make cells more resistant or more sensitive to these drug; suggesting that this approach might help overcome the serious resistance problem in tumours. So, (i) we explained this study to many patients enrolling in clinical trials using these drugs. They donated blood specimens that we want to test to see if analyse for NmU and miR-X can predict those who will/won't respond; (ii) we are at a stage where we now need to progress our work of "tweaking" NmU and miR-X to see if we can help overcome this resistance in a living organism.
  • Funding Agency
    • Health Research Board
  • Date From
    • Feb. 2014
  • Date To
    • Feb. 2017
  • Title
    • European Network on Microvesicles & Exosomes in Health and Disease
  • Summary
    • Microvesicles and Exosomes (ME) have attracted much recent interest because of their potential functions, use as disease biomarkers and possible therapeutic exploitation. Due to their enormous relevance, through nationally-funded projects throughout Europe, this relatively new field of research is quickly expanding. There are, however, many associated issues that need to be addressed to ensure optimal research performance and collation and cross-interpretation of data. These issues range from the need to derive a consensus on fundamental guidelines/nomenclature and optimal techniques for vesicle isolation and analysis, to more advanced issues such as collating emerging data and expertise towards better understanding, and thus exploiting, the physiological and pathological roles of ME. There is also urgency to identify gaps in ME knowledge and how best collaborative research can address these questions. This Consrtium creates a network of European experts, fostering a multidisciplinary approach to enhance both basic understanding and translational potential of ME.
  • Funding Agency
    • EU H2020
  • Date From
    • Jan 2013
  • Date To
    • Dec 2018
  • Title
    • Breast-PREDICT
  • Summary
    • Breast-PREDICT is a country-wide collaboration between experts in the area of breast cancer research, funded by the Irish Cancer Society. This 'virtual Centre' was launched in October 2013 and will run for a period of five years. Breast-PREDICT brings together researchers from six academic institutions across Ireland: UCD, TCD, RCSI, DCU, NUIG and UCC, and a nationwide clinical trials group, ICORG. We collect information and tumour samples from nearly every breast cancer patient in the country, with their consent. Using these valuable resources, we will improve our understanding of how this disease can spread and become resistant to treatment, and find ways to combat this with new and better therapies. This is a multi-disciplinary Centre, which unites breast cancer experts with different skills, to work towards a common goal.
  • Funding Agency
    • Irish Cancer Society
  • Date From
    • Nov. 2013
  • Date To
    • Oct. 2018
  • Title
    • Biomarkers & Therapeutics Targets: MeS, Diabetes and Cancer
  • Summary
    • In vitro, in vivo and clinical trials studies including researchers from ireland, Denmark, The Netherlands, and Germany to identify and validate biomarkers & new therapeutics targets of potential relevant to metabolic syndrome, diabetes and cancer
  • Funding Agency
    • Danish Strategic Research Council / EU
  • Date From
    • March 2013
  • Date To
    • Feb. 2016
  • Title
    • Exploring the Relevance of Exosomes in Cancer
  • Funding Agency
    • IRCSET
  • Date From
    • Oct 2011
  • Date To
    • Sept 2014
  • Title
    • Marie Keating Foundation PhD Scholarship at Trinity College Dublin
  • Summary
    • Better ways of assessing anti-cancer drugs in the laboratory to increase their success for breast cancer patients
  • Funding Agency
    • Marie Keating Foundation, Trinity Foundation, TCD
  • Date From
    • April 2011
  • Date To
    • March 2015
  • Title
    • Marie Keating Foundation PhD Scholarship at Trinity College Dublin
  • Summary
    • Developing blood tests for earlier diagnosis & optimal treatment selection for breast cancer patients
  • Funding Agency
    • Marie Keating Foundation, Trinity Foundation, TCD
  • Date From
    • Jan 2010
  • Date To
    • Jan 2015
  • Title
    • Molecular Therapeutics for Cancer
  • Summary
    • This Cluster of scientific, clinical, industrial partners, with support from the All Ireland Clinical Oncology Research Group (ICORG) focusses on Molecular Therapeutics for Cancer. This fully-integrated translational cancer drug discovery and development programme will significantly benefit cancer patients. Our industry patners include SRC's Industry Partners are GlaxoSmithKline, Pfizer, Merck Sharpe & Dohme, Novartis, Roche, and Amgen. SFIs support for this SRC is €7.3m.
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • Oct 2009
  • Date To
    • Sept 2014
  • Title
    • New Diagnostic and Prognostic Biomarkers for Age-Related Macular Degeneration
  • Funding Agency
    • IRCSET
  • Date From
    • Oct 2010
  • Date To
    • Sept 2013
  • Title
    • Characterisation of 2 Novel mRNAs Present in Breast Tumours - but not Normal Breast Tissue - with potential as Therapeutic Targets & Diagnostic/Prognostic Biomarkers.
  • Summary
    • We have identified, using whole genome expression microarray analysis of a large bank of breast cancer and normal breast biopsies, two novel poorly characterised transcripts which do not occur in normal breast but are found in more than one third of breast cancer biopsies. Kaplan-Meier, X2 and Cox Regression analyses showed that expression of each of these transcripts is significantly associated with poor prognosis. We propose to characterise and investigate the function of these two genes, which were not present in previously published microarray analyses, in order to assess their possible importance in breast cancer cell biology, as therapeutic targets and as diagnostic/prognostic/predictive markers. In this project, we propose to isolate and sequence the full length cDNAs, and to investigate homologies to better characterised genes with known roles within the cell. We will investigate the functions of these genes in relation to properties such as cell growth rate, cell survival, cell division, invasion, drug resistance and soft agar colony formation, in a panel of breast cancer cell lines using cDNA and SiRNA transfections. qRT-PCR will be used to choose cell lines most appropriate for up- or down-regulation of expression. Peptides from the predicted protein structure will be used to raise antibodies for Western Blotting and immunocytochemistry. GFP-tagged cDNAs will be prepared in order to investigate subcellular localisation of the gene products. By analogy with the her2/herceptin diagnostic/therapeutic pairing, we hope this project may lead to identification of new specific targets for diagnosis and therapy of subsets of breast carcinoma patients.
  • Funding Agency
    • Health Research Board
  • Date From
    • October 2006
  • Date To
    • March 2010
  • Title
    • Biomarkers (mRNAs, miRNAs, proteins) for Type 1 & Type 2 Diabetes
  • Summary
    • Type 2 diabetes mellitus (T2DM) is associated with reduced β-cell function, relatively reduced β-cell mass and insulin resistance. Serum biomarkers of β-cell mass and/or function have not been described. Amplifiable mRNAs, which have been detected in conditioned medium from cultures of insulin-producing animal cell-lines, if detectable in human serum, could serve as markers of β-cell mass. We attempted to detect these mRNAs in serum from patients with newly diagnosed T2DM and compared them to healthy controls. We recruited T2DM subjects (mean DM duration 4.36±2.33 months) and controls (age, gender and BMI matched). Medical history, physical exam and fasting bloods were obtained. Serum mRNA levels were analysed using real time quantitative reverse transcription-PCR. Two mRNAs, thioredoxin interacting protein (Txnip) and early growth response factor 1 (Egr1), previously associated with cell-line glucose responsiveness, were detected.Levels of Egr1 were lower and levels of Txnip tended to be higher in T2DM. Egr1 level correlated positively with smoking history in pack-years (ρ=0.485, p=0.042), total (ρ=0.554, p=0.017) and LDL cholesterol (ρ= 0.495, p= 0.043). Txnip level correlated positively with age (ρ= 0.471, p=0.042) and HOMA%S (ρ= 0.489, p= 0.034) but not with smoking history or cholesterol level. To our knowledge, this is a first description of detectable serum mRNAs possibly linked to the diagnosis of diabetes. Significance of this finding is unclear at present and confounding variables may have an effect on these results.
  • Funding Agency
    • Higher Education Authority & Seed Funding
  • Date From
    • Oct 2008
  • Date To
    • Jan 2011
  • Title
    • Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer
  • Summary
    • The standard of care for hormone refractory prostate cancer (HRPC) is taxotere (generally 2-3 weekly; for 10 cycles). This treatment increases overall survival (OS) by, on average, 2.5 months. Mechanisms are not currently available to determine (i) those patients who are most suitable/would benefit from this treatment; (ii) why this benefit is short-term (why relapse/resistance occurs); and (iii) which patients are unlikely to respond to taxanes and so should potentially be offered targeted therapies. The primary objective is to establish if gene expression in circulating tumour cells (CTC) from HRPCs patients is predictive of response to therapy.
  • Funding Agency
    • Adnagen
  • Date From
    • Jan 2008
  • Date To
    • Dec 2010
  • Title
    • LUNGMARK
  • Summary
    • Discovery & validation of panels of new diagnostic and theranostic blood-Based biomarkers for lung cancer
  • Funding Agency
    • Enterprise Ireland (under National Strategic Dev. Plan 2007-2013 co-financed by ERDF)
  • Date From
    • 5 Oct 2009
  • Date To
    • 31 March 2011

Keywords

Apoptosis; Apoptosis, molecular control; Bioinformatics; Biology; Biology and therapy of myeloma; Biomedical sciences; Breast cancer; Cancer genetics and cell biology including metastasis; Cell and tissue development; Cell and tissue maintenance, repair and ageing; Clinical research, trials; Diabetes and diabetic complications; Diagnostics; DNA transcription and translation; Drug development and evaluation; Drug discovery, profiling, targeting; Embryonic development; Endocrine function and disease; Gene targeting in breast cancer; Gene therapy; Gene transcription in human cancer; Human genetics; Immunoassays; In vitro testing, trial methods; Mammilian and human genetics and genomics; Medical Sciences, Research; Membrane and protein trafficking; Multiple Myeloma; Oncogenes, apoptosis and tumour development; Pathology; Prostate cancer; Regulatory methods of gene expression; RNA processing, stability and degradation; Stem Cell biology and hematopoiesis; Therapeutic and Clinical oncology

Recognition

Memberships

Chair, European Network on Microvesicles and Exosomes in Health and Disease 2013 – ------

Invited Member of Irish Association for Cancer Research (IACR) Research Capacity Building Committee 2011 – present

Editorial Board Member for Encyclopaedia of Bioscience Frontier in Bioscience 2007-present

Editorial Board Member for Cancer Genomics & Proteomics 2006-present

Editor of Anticancer Research May 2004; Aug. 2007

Guest-Editor of book volume of Current Cancer Drug Targets entitled "Mechanisms of Cancer Drug Sensitivity & Resistance: A Translational Approach" 2009

Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling 2009-2010

International Conference Organisng Committee Member: 8th International Conference of Anticancer Research, Kos 2008

International Conference Organisng Committee Member: Global mRNA & Protein Expression Analysis for Biomedical Applications & Biopharmaceutical Production, Dublin 2006

International Conference Organisng Committee Member: International Islet and Pancreas Transplantation Association Congress 2003

International Conference Organisng Committee Member: 1st International Conference Biotechnology Cancer and Drug Resistance 2003

International Conference Organisng Committee Member: 7th International Conference of Anticancer Research, Corfu 2004

Invited Member of the International Institute of Anticancer Research (IIAR) Scientific Advisory Board 2006-present

Deputy-President of the Irish Branch of the European Tissue Culture Society (ETCS) 2007-present

Director/Council Member of the Irish Association for Cancer Research (IACR) 2008-present

Member of the European Association for Cancer Research (EACR) 2006-present

Research Specialist: All Ireland Clinical Oncology Research Group (& Principal Investigator on Phase I & II trials) 2005-present

Member of Irish Network of Stem-Cell Investigators (INNSI) 2004-present

Member of the European Association for the Study of Diabetes (EASD) 2002-present

Board Member of the National Institute for Cellular Biotechnology 2002-present

Member of the National Institute for Cellular Biotechnology Scientific Advisory Board 2002-present

Elected Member on Dublin City University's Research Advisory Panel 2002-2008

Elected Member on Dublin City University's Faculty of Science & Health Research Committee 2003-2008


Last updated 9 September 2016 by School of Pharmacy & Pharmaceutical Sciences (Email).